 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years and account for ~ 20% of COVID-19 deaths |
(Université de Paris) (Université de Paris) (Université de Paris) (Université de Paris) (Université de Paris) (The Rockefeller University) (The Rockefeller University) (Hiroshima University) (Hospital Universitari Vall d'Hebron. Institut de Recerca) (Université de Paris) (Hospital Universitari Vall d'Hebron. Institut de Recerca) (The Rockefeller University) (University of Tartu) (Université de Paris) (University of Tartu) (Université Paris Est Créteil) (Hôpital Avicenne (Bobigny, França)) (Sorbonne Université) (Université de Paris) (Institut Pasteur de Lille (França)) (Etablissement Français du Sang) (Etablissement Français du Sang) (Hospital Universitario Infanta Leonor) (Hospices Civils de Lyon) (Hospices Civils de Lyon) (International Center of Research in Infectiology) (Hospital Universitari Vall d'Hebron. Institut de Recerca) (Hôpitaux Universitaires de Marseille (França)) (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) (Université de Paris) (Université Paris-Diderot) (Université Paris-Diderot) (Biomedical Research Foundation of the Academy of Athens) (Necker Hospital for Sick Children) (Institute for Systems Biology (Estats Units d'Amèrica)) (Universidad de Antioquia) (Universidad del Rosario (Colòmbia)) (Azienda Ospedaliera Spedali Civili di Brescia (Brescia, Itàlia)) (Università degli Studi di Milano-Bicocca) (University of Pavia) (Uniformed Services University of the Health Sciences (Bethesda, Estats Units d'Amèrica)) (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) (The University of British Columbia) (The Rockefeller University) (Universidad de Antioquia) (Université de Paris) (Université de Paris) (Université de Paris Cité) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Ghent University Hospital (Gant, Bèlgica)) (Goce Delcev University (Macedònia)) (University of California) (Bilkent University) (Necmettin Erbakan Üniversitesi) (Hassan II University) (Hassan II University) (Universidad de Antioquia) (Centre Hospitalier Universitaire de Saint-Étienne) (Karolinska Institutet (Estocolm, Suècia)) (Karolinska Institutet (Estocolm, Suècia)) (Institut Pasteur de Lille) (Tel Aviv Sourasky Medical Center) (Feinstein Institutes for Medical Research) (Università Vita Salute San Raffaele) (Università Vita Salute San Raffaele) (IRCCS Ospedale San Raffaele (Milà, Itàlia)) (IRCCS Ospedale San Raffaele (Milà, Itàlia)) (Universidade de São Paulo) (Fundación Rioja Salud) (Universidade de São Paulo) (Universidade de São Paulo) (Amsterdam Universitair Medische Centra (Amsterdam, Països Baixos). Amsterdam Neuroscience) (Shupyk National Healthcare University of Ukraine) (I.Horbachevsky Ternopil National Medical University) (Tokyo Medical and Dental) (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) (Garvan Institute of Medical Research (Darlinghurst, Austràlia)) (St Vincent's Clinical School) (Institut Pasteur) (Institut Pasteur) (Dmitriy Rogachev National Center for Pediatric Hematology (Moscou, Rússia)) (Dmitriy Rogachev National Center for Pediatric Hematology (Moscou, Rússia)) (The University of Hong Kong) (The University of Hong Kong) (Tours University Medical Center) (Université de Tours) (Amsterdam Universitair Medische Centra (Amsterdam, Països Baixos). Amsterdam Neuroscience) (Universidad de La Sabana) (Hôpital Edouard Herriot (Lyon, França)) (Hôpital Edouard Herriot (Lyon, França)) (The Rockefeller University) (Tel Aviv University) (Tel Aviv University) (University Hospitals Leuven (Bèlgica)) (Laboratory of Inborn Errors of Immunity (Bèlgica)) (Tallaght University Hospital) (Trinity College Dublin) (University of Sharjah) (University of Sharjah) (Sorbonne Université) (King Fahad Hospital of the University) (Hospital Universitari de Bellvitge) (Hospital Universitari de Bellvitge) (Research Institute-McGill University Health Centre) (Research Institute-McGill University Health Centre) (Copenhagen University Hospital) (Universidade de São Paulo) (Instituto de Pesquisa Pelé Pequeno Príncipe) (The Rockefeller University) (Centre de Recherche des Cordeliers) (Swiss Institue of Bioinformatics) (Yale Center for Genome Analysis) (Yale University) (University of California) (Université de Paris) (Université de Paris) (Université de Paris) (Biomedical Research Foundation of the Academy of Athens) (Université de Paris) (Institut d'Investigació Biomèdica de Bellvitge) (University of Tartu) (Aarhus University) (Université de Bordeaux) (Aix-Marseille Université) (Université Paris-Saclay (França)) (Hospital Universitari Vall d'Hebron. Institut de Recerca) (Hospital Universitari Vall d'Hebron. Institut de Recerca) (Sorbonne Université) (Hospital Universitari de Bellvitge) (Institut Pasteur de Lille) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Feinstein Institutes for Medical Research) (IRCCS Ospedale San Raffaele (Milà, Itàlia)) (Hospital Universitario de Gran Canaria Dr. Negrín) (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) (University of Tartu) (Hiroshima University) (Université de Paris) (Université de Paris) (The Rockefeller University) (Université de Franche-Comté) (Université de Paris) (Université de Paris) (Université de Paris) (Howard Hughes Medical Institute)| Data: | 2021 |
| Resum: | Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100pg/mL, in 1/10 dilutions of plasma) in 13. 6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6. 5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1,124 deceased patients (aged 20 days-99 years; mean: 70 years). Moreover, another 1. 3% of patients with critical COVID-19 and 0. 9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show, in a sample of 34,159 uninfected subjects from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or -ω are present in 0. 18% of individuals aged between 18 and 69 years, 1. 1% between 70 and 79 years, and 3. 4% > 80 years. Moreover, the proportion of subjects carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals < 70 years, 2. 3% between 70 and 80 years, and 6. 3% > 80 years. By contrast, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over-80s, and total fatal COVID-19 cases. Autoantibodies neutralizing type I IFNs increase in prevalence over 60 years of age and underlie about 20% of all fatal COVID-19 cases. |
| Ajuts: | European Commission 824110 European Commission 948959 Instituto de Salud Carlos III PI17/00660 |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Publicat a: | Science immunology, Vol. 6 (august 2021) , ISSN 2470-9468 |
